Clinical Effects of Ringers Lactate Versus Sterofundin/ Plasmalyte Solution in Patients With Sepsis

NCT ID: NCT07239713

Last Updated: 2025-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-15

Study Completion Date

2026-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to compare the clinical effects of using Ringer's Lactate and Sterofundin/ Plasmalyte as maintenance fluids in adult patients who have undergone abdominal surgery and are septic.

The primary outcome will be the change in serum lactate levels. Secondary outcomes will include renal function parameters, qSOFA scores, and the incidence of postoperative complications within the first 72 hours following surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this clinical trial is to compare the clinical effects of using Ringer's Lactate and Sterofundin/PlasmaLyte as maintenance fluids in adult patients who have undergone abdominal surgery and are septic.

The primary outcome will be the change in serum lactate levels. Secondary outcomes will include renal function parameters, qSOFA scores, and the incidence of postoperative complications within the first 72 hours following surgery.

The main questions it aims to answer are:

1. Does the choice of fluid produce different outcomes in this patient population?
2. If yes, then which fluid produces better outcomes?

Enrolled patients will be randomly assigned Ringer's Lactate or Sterofundin for intravenous infusion. The volume, infusion rate and additive content will be determined by the treating clinicians. The intervention will last for 72 hours after patients' enrolment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Abdominal Surgery Sepsis Abdominal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ringer's Lactate Group

This group will receive RInger's Lactate as maintenance fluid.

Group Type ACTIVE_COMPARATOR

Ringer's Lactate Crystalloid Solutions

Intervention Type OTHER

A balanced crystalloid solution containing sodium, potassium, calcium, chloride, and lactate as a buffer.

Used at a standard maintenance rate for adult postoperative patients.

Steroundin Group

This group will receive Sterofundin as maintenance fluid.

Group Type EXPERIMENTAL

Sterofundin (Bolus of crystalloids)

Intervention Type OTHER

A balanced, multi-electrolyte crystalloid solution containing acetate and malate as buffers instead of lactate.

Designed to more closely match plasma electrolyte composition, with a lower chloride concentration than RL.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ringer's Lactate Crystalloid Solutions

A balanced crystalloid solution containing sodium, potassium, calcium, chloride, and lactate as a buffer.

Used at a standard maintenance rate for adult postoperative patients.

Intervention Type OTHER

Sterofundin (Bolus of crystalloids)

A balanced, multi-electrolyte crystalloid solution containing acetate and malate as buffers instead of lactate.

Designed to more closely match plasma electrolyte composition, with a lower chloride concentration than RL.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Underwent Abdominal Surgery and postoperative length of stay is more than 24 hours
* ASA 1 to 4
* Diagnosis of sepsis (qSOFA score 2 or more)

Exclusion Criteria

* Patients with Renal failure/hepatic failure/severe metabolic acidosis
* Patients requiring renal replacement therapy prior to enrolment
* Patients with suspected poisoning
* Pregnant women
* Patients having solitary kidney
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CMH Lahore Medical College and Institute of Dentistry

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Syed A Jafri, MBBS

Role: STUDY_CHAIR

Combined military hospital lahore

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Combined Military Hospital Lahore

Lahore, Punjab Province, Pakistan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Khadija Dr. Zubair, MBBS

Role: CONTACT

+923211403262

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Brig. Syed Asadullah Jafri

Role: primary

+923212427770

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

563/2024

Identifier Type: -

Identifier Source: org_study_id